WeVote
Log In

Bill

Bill

A 8136

Relates to prescription drug cost-sharing assistance

2025 Regular Session Introduced by David Weprin

A 8136 aims to cut patients' prescription drug out-of-pocket costs by expanding cost-sharing assistance and clarifying insurer/program duties.

REFERRED TO INSURANCE
0
WeVote Research Nonpartisan
Bill Summary · A 8136

Summary: Assembly Bill A 8136 — Relates to prescription drug cost-sharing assistance

Quick overview

  • Bill number: A 8136
  • Title: Relates to prescription drug cost-sharing assistance
  • Status: REFERRED TO INSURANCE
  • Introduced: May 1, 2025
  • Sponsor: David Weprin (primary)
  • Companion/twins: S 7900 (companion)

Purpose and intent

Based on the title, the bill addresses prescription drug cost-sharing assistance. The available information does not include the full text, so the specific policy goals (e.g., expanding eligibility, creating a state-funded program, or clarifying insurer obligations) cannot be stated definitively. In general, bills with this focus aim to reduce out-of-pocket costs for prescription drugs or to formalize programs that help patients meet cost-sharing requirements.

Key provisions (information not provided)

The complete bill text is not provided here. As such, exact provisions, including:
- who would qualify for any cost-sharing assistance,
- how assistance would be funded or administered,
- the role of insurers, pharmacies, or manufacturers,
- reporting, oversight, or enforcement mechanisms,
- any caps, thresholds, or sunset provisions,
- or interaction with existing programs,
cannot be enumerated from the available summary.

If enacted, the bill would define these elements through its statutory language. Interested readers should consult the official bill text for precise provisions.

Who would be affected

  • Patients and consumers: those who incur prescription drug costs and may benefit from cost-sharing assistance.
  • Insurance issuers and pharmacy benefit managers: potential changes to requirements, definitions, or program administration.
  • Pharmacists and pharmacies: implementation of any new cost-sharing assistance mechanisms.
  • State agencies and program administrators: oversight, funding administration, reporting duties.
  • Drug manufacturers or program sponsors: potential impacts if the bill includes manufacturer-based assistance provisions.

Procedural and timeline aspects

  • Introduced and referred to the Assembly Committee on Insurance on May 1, 2025.
  • Companion bill: S 7900 in the Senate (also listed as a companion in the provided information).
  • Next steps typically include committee hearings, potential amendments, and floor votes in both houses, followed by consideration by the governor if passed.
  • For current status and text, monitor the official New York State Assembly and Senate bill portals.

Additional notes

  • The summary reflects the information provided. For a substantive understanding, review the official bill text of A 8136 (and S 7900) and any fiscal notes or committee reports once available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.